Biotechnology company Immutep (ASX:IMM) obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.
The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival of 12.7 months, and a 24-month overall survival rate of 81%, the filing said.
Results also show no new safety signals.
Insight-003, led by the Frankfurt Institute of Clinical Cancer Research, is nearing patient enrollment completion, with further data from the trial expected in 2025, according to the filing.
Immutep shares rose past 8% in midday trade Thursday.
Price (AUD): $0.34, Change: $+0.03, Percent Change: +8.06%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。